{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:41:05Z","timestamp":1789400465307,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The majority of cancers remain incurable due to limited therapeutic responses in malignancies with high-risk genetic mutations such as\n                    <jats:italic>TP53<\/jats:italic>\n                    . Building on the success of mRNA vaccine technology, we investigated circular RNA (circRNA) therapeutics and identified hsa_circp53_0041947, a\n                    <jats:italic>TP53<\/jats:italic>\n                    -derived circRNA in multiple myeloma (MM). The hsa_circp53_0041947 encodes a functional peptide (circp53\u2013209aa) demonstrating p53 mutation-independent anti-MM effects through CypD\/TRAP1\/HSP90 complex-mediated mechanisms. Specifically, circp53\u2013209aa activated cyclophilin D (CypD) isomerase activity at the circp53\u2013209aa-R175 site, triggering mitochondrial permeability transition pore opening and subsequent mitochondrial apoptosis. To enable targeted delivery, we engineered extracellular vesicle (EV) systems, E7-Lamp2b-EVs and Her2-Lamp2b-EVs, for MM and colorectal cancer, respectively. Circp53-EVs administration achieved tumor-selective growth inhibition in both malignancies. Our study establishes engineered circp53-EVs as a versatile therapeutic platform, demonstrating the translational potential of circRNA-based strategies for refractory cancers with\n                    <jats:italic>TP53<\/jats:italic>\n                    pathway alterations.\n                  <\/jats:p>","DOI":"10.1038\/s12276-025-01506-0","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:03:34Z","timestamp":1754006614000},"page":"1711-1726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Extracellular vesicle-mediated delivery of circp53 suppresses the progression of multiple cancers by activating the CypD\/TRAP\/HSP90 pathway"],"prefix":"10.1038","volume":"57","author":[{"given":"Xichao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinggang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhancheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"1506_CR1","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/bjh.13298","volume":"169","author":"P Asvadi","year":"2015","unstructured":"Asvadi, P. et al. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br. J. Haematol. 169, 333\u2013343 (2015).","journal-title":"Br. J. Haematol."},{"key":"1506_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/jcm7040064","volume":"7","author":"SA Azer","year":"2018","unstructured":"Azer, S. A. MDM2-p53 interactions in human hepatocellular carcinoma: what is the role of nutlins and new therapeutic options?. J. Clin. Med. 7, 64 (2018).","journal-title":"J. Clin. Med."},{"key":"1506_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/hep.31829","volume":"74","author":"T Boerner","year":"2021","unstructured":"Boerner, T. et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology 74, 1429\u20131444 (2021).","journal-title":"Hepatology"},{"key":"1506_CR4","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.21037\/gs-21-481","volume":"10","author":"W Chen","year":"2021","unstructured":"Chen, W. et al. Upregulated circRAD18 promotes tumor progression by reprogramming glucose metabolism in papillary thyroid cancer. Gland Surg. 10, 2500\u20132510 (2021).","journal-title":"Gland Surg."},{"key":"1506_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.76","volume":"7","author":"M Chin","year":"2017","unstructured":"Chin, M. et al. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival. Blood Cancer J. 7, e610 (2017).","journal-title":"Blood Cancer J."},{"key":"1506_CR6","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk, J. E. et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303, 1010\u20131014 (2004).","journal-title":"Science"},{"key":"1506_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"1506_CR8","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1506_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1182\/blood.2019004309","volume":"137","author":"J Corre","year":"2021","unstructured":"Corre, J., Munshi, N. C. & Avet-Loiseau, H. Risk factors in multiple myeloma: is it time for a revision? Blood 137, 16\u201319 (2021).","journal-title":"Blood"},{"key":"1506_CR10","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie, E. J. et al. Endometrial cancer. Lancet 399, 1412\u20131428 (2022).","journal-title":"Lancet"},{"key":"1506_CR11","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/nm.1868","volume":"14","author":"H Du","year":"2008","unstructured":"Du, H. et al. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer\u2019s disease. Nat. Med. 14, 1097\u20131105 (2008).","journal-title":"Nat. Med."},{"key":"1506_CR12","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.stem.2022.09.001","volume":"29","author":"S Ferrari","year":"2022","unstructured":"Ferrari, S. et al. Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells. Cell Stem Cell 29, 1428\u20131444 (2022).","journal-title":"Cell Stem Cell"},{"key":"1506_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbrc.2013.08.052","volume":"440","author":"T Fujiwara","year":"2013","unstructured":"Fujiwara, T. & Morimoto, K. A compound CP-31398 suppresses excitotoxicity-induced neurodegeneration. Biochem. Biophys. Res. Commun. 440, 359\u2013363 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1506_CR14","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Investigators, pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1506_CR15","doi-asserted-by":"publisher","first-page":"16296","DOI":"10.1021\/acsami.9b02016","volume":"11","author":"Y Gao","year":"2019","unstructured":"Gao, Y. et al. pH\/redox dual-responsive polyplex with effective endosomal escape for codelivery of siRNA and doxorubicin against drug-resistant cancer cells. ACS Appl. Mater. Interfaces 11, 16296\u201316310 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"1506_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-021-01380-0","volume":"20","author":"C Gu","year":"2021","unstructured":"Gu, C. CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma. Mol. Cancer 20, 84 (2021).","journal-title":"Mol. Cancer"},{"key":"1506_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.breast.2022.07.002","volume":"65","author":"Y Guo","year":"2022","unstructured":"Guo, Y. et al. Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients. Breast 65, 55\u201360 (2022).","journal-title":"Breast"},{"key":"1506_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug Discov. 22, 127\u2013144 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1506_CR19","first-page":"297","volume":"1","author":"ML Immordino","year":"2006","unstructured":"Immordino, M. L., Dosio, F. & Cattel, L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297\u2013315 (2006).","journal-title":"Int. J. Nanomed."},{"key":"1506_CR20","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1007\/s00018-017-2502-4","volume":"74","author":"S Javadov","year":"2017","unstructured":"Javadov, S., Jang, S., Parodi-Rullan, R., Khuchua, Z. & Kuznetsov, A. V. Mitochondrial permeability transition in cardiac ischemia-reperfusion: whether cyclophilin D is a viable target for cardioprotection? Cell. Mol. Life Sci. 74, 2795\u20132813 (2017).","journal-title":"Cell. Mol. Life Sci."},{"key":"1506_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-017-0160-y","volume":"20","author":"A Jeyaram","year":"2017","unstructured":"Jeyaram, A. & Jay, S. M. Preservation and storage stability of extracellular vesicles for therapeutic applications. AAPS J. 20, 1 (2017).","journal-title":"AAPS J."},{"key":"1506_CR22","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"1506_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1172\/JCI37613","volume":"119","author":"BH Kang","year":"2009","unstructured":"Kang, B. H. et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest 119, 454\u2013464 (2009).","journal-title":"J. Clin. Invest"},{"key":"1506_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s41418-022-00989-y","volume":"29","author":"MC Kennedy","year":"2022","unstructured":"Kennedy, M. C. & Lowe, S. W. Mutant p53: it\u2019s not all one and the same. Cell Death Differ. 29, 983\u2013987 (2022).","journal-title":"Cell Death Differ."},{"key":"1506_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13046-022-02276-7","volume":"41","author":"X Tang","year":"2022","unstructured":"Tang, X. et al. A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing. J. Exp. Clin. Cancer Res. 41, 85 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1506_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41392-021-00746-6","volume":"6","author":"X Tang","year":"2021","unstructured":"Tang, X. et al. BUB1B and circBUB1B_544aa aggravate multiple myeloma malignancy through evoking chromosomal instability. Signal. Transduct. Target. Ther 6, 361 (2021).","journal-title":"Transduct. Target. Ther"},{"key":"1506_CR27","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41422-019-0231-y","volume":"29","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. BH3-only proteins target BCL-xL\/MCL-1, not BAX\/BAK, to initiate apoptosis. Cell Res. 29, 942\u2013952 (2019).","journal-title":"Cell Res."},{"key":"1506_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1158\/2159-8290.CD-23-0656","volume":"14","author":"SPal Choudhuri","year":"2024","unstructured":"Choudhuri, S. Pal et al. Acquired cross-resistance in small cell lung cancer due to extrachromosomal DNA amplification of MYC paralogs. Cancer Discov. 14, 804\u2013827 (2024).","journal-title":"Cancer Discov."},{"key":"1506_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12943-023-01790-2","volume":"22","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Metal-enriched HSP90 nanoinhibitor overcomes heat resistance in hyperthermic intraperitoneal chemotherapy used for peritoneal metastases. Mol. Cancer 22, 95 (2023).","journal-title":"Mol. Cancer"},{"key":"1506_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ncb1123","volume":"6","author":"JI Leu","year":"2004","unstructured":"Leu, J. I., Dumont, P., Hafey, M., Murphy, M. E. & George, D. L. Mitochondrial p53 activates Bak and causes disruption of a Bak\u2013Mcl1 complex. Nat. Cell Biol. 6, 443\u2013450 (2004).","journal-title":"Nat. Cell Biol."},{"key":"1506_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1152\/physrev.00013.2006","volume":"87","author":"G Kroemer","year":"2007","unstructured":"Kroemer, G., Galluzzi, L. & Brenner, C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87, 99\u2013163 (2007).","journal-title":"Physiol. Rev."},{"key":"1506_CR32","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.7150\/thno.98214","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Developing an enhanced chimeric permuted intron-exon system for circular RNA therapeutics. Theranostics 14, 5869\u20135882 (2024).","journal-title":"Theranostics"},{"key":"1506_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12943-021-01476-7","volume":"21","author":"Y Ling","year":"2022","unstructured":"Ling, Y. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. Mol. Cancer 21, 8 (2022).","journal-title":"Mol. Cancer"},{"key":"1506_CR34","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1093\/annonc\/mdr568","volume":"23","author":"S Bondong","year":"2012","unstructured":"Bondong, S. et al. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation. Ann. Oncol. 23, 1795\u20131802 (2012).","journal-title":"Ann. Oncol."},{"key":"1506_CR35","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.3390\/ijms25126606","volume":"25","author":"Y Jeong","year":"2024","unstructured":"Jeong, Y., Han, J. & Jang, K. L. Reactive oxygen species induction by hepatitis B virus: implications for viral replication in p53-positive human hepatoma cells. Int. J. Mol. Sci. 25, 6606 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1506_CR36","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","volume":"23","author":"S Poulain","year":"2017","unstructured":"Poulain, S. et al. TP53 mutation and its prognostic significance in Waldenstrom's macroglobulinemia. Clin. Cancer Res. 23, 6325\u20136335 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1506_CR37","doi-asserted-by":"crossref","unstructured":"Cisse, M. Y. et al. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma. Sci. Transl. Med. 12, eaay2163 (2020).","DOI":"10.1126\/scitranslmed.aay2163"},{"key":"1506_CR38","first-page":"1684","volume":"55","author":"YS Guan","year":"2006","unstructured":"Guan, Y. S. et al. p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. Gut 55, 1684 (2006).","journal-title":"Gut"},{"key":"1506_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1126\/science.adh7950","volume":"384","author":"NJ Boon","year":"2024","unstructured":"Boon, N. J. et al. DNA damage induces p53-independent apoptosis through ribosome stalling. Science 384, 785\u2013792 (2024).","journal-title":"Science"},{"key":"1506_CR40","doi-asserted-by":"crossref","unstructured":"Zhou, H. et al. Effects of melatonin on fatty liver disease: the role of NR4A1\/DNA-PKcs\/p53 pathway, mitochondrial fission, and mitophagy. J. Pineal Res. 64, e12450 (2018).","DOI":"10.1111\/jpi.12450"},{"key":"1506_CR41","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-021-00433-y","volume":"23","author":"M Bonora","year":"2022","unstructured":"Bonora, M., Giorgi, C. & Pinton, P. Molecular mechanisms and consequences of mitochondrial permeability transition. Nat. Rev. Mol. Cell Biol. 23, 266\u2013285 (2022).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1506_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cmet.2019.05.009","volume":"30","author":"Q Li","year":"2019","unstructured":"Li, Q. et al. CircACC1 regulates assembly and activation of AMPK complex under metabolic stress. Cell Metab. 30, 157\u2013173.e157 (2019).","journal-title":"Cell Metab."},{"key":"1506_CR43","first-page":"231","volume":"42","author":"S Oppedal","year":"1974","unstructured":"Oppedal, S. The dental student: what he expects, how he studies and how he considers his professional career. Dent. Cadmos 42, 231\u2013240 (1974).","journal-title":"Dent. Cadmos"},{"key":"1506_CR44","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41576-024-00806-x","volume":"26","author":"E O\u2019Leary","year":"2025","unstructured":"O\u2019Leary, E., Jiang, Y., Kristensen, L. S., Hansen, T. B. & Kjems, J. The therapeutic potential of circular RNAs. Nat. Rev. Genet 26, 230\u2013244 (2025).","journal-title":"Nat. Rev. Genet"},{"key":"1506_CR45","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1349-7006.2011.02105.x","volume":"103","author":"T Ueno","year":"2012","unstructured":"Ueno, T. et al. High-throughput resequencing of target-captured cDNA in cancer cells. Cancer Sci. 103, 131\u2013135 (2012).","journal-title":"Cancer Sci."},{"key":"1506_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00582-7","volume":"9","author":"A Pal","year":"2023","unstructured":"Pal, A. et al. Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants. npj Breast Cancer 9, 78 (2023).","journal-title":"npj Breast Cancer"},{"key":"1506_CR47","doi-asserted-by":"publisher","first-page":"78397","DOI":"10.18632\/oncotarget.19228","volume":"8","author":"VB O\u2019Leary","year":"2017","unstructured":"O\u2019Leary, V. B. et al. The circRNA interactome\u2014innovative hallmarks of the intra- and extracellular radiation response. Oncotarget 8, 78397\u201378409 (2017).","journal-title":"Oncotarget"},{"key":"1506_CR48","doi-asserted-by":"crossref","unstructured":"Okholm, T. L. H. et al. Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression. Genome Med. 12, 112 (2020).","DOI":"10.1186\/s13073-020-00812-8"},{"key":"1506_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molcel.2020.10.022","volume":"80","author":"KT Bieging-Rolett","year":"2020","unstructured":"Bieging-Rolett, K. T. et al. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Mol. Cell 80, 452\u2013469 (2020).","journal-title":"Mol. Cell"},{"key":"1506_CR50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.tcb.2024.10.006","volume":"35","author":"J Jansen","year":"2024","unstructured":"Jansen, J. & Dobbelstein, M. MDM4 exon skipping upon dysfunctional ribosome assembly. Trends Cell Biol 35, 544\u2013547 (2024).","journal-title":"Trends Cell Biol"},{"key":"1506_CR51","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/s41418-023-01190-5","volume":"30","author":"Z Chen","year":"2023","unstructured":"Chen, Z. et al. N6-Methyladenosine hypomethylation of circGPATCH2L regulates DNA damage and apoptosis through TRIM28 in intervertebral disc degeneration. Cell Death Differ. 30, 1957\u20131972 (2023).","journal-title":"Cell Death Differ."},{"key":"1506_CR52","doi-asserted-by":"crossref","unstructured":"Manso, A. M. et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease. Sci. Transl. Med. 12, eaax1744 (2020).","DOI":"10.1126\/scitranslmed.aax1744"},{"key":"1506_CR53","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. Nat. Nanotechnol. 14, 388\u2212397 (2019).","DOI":"10.1038\/s41565-019-0381-6"}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01506-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01506-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01506-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T10:02:54Z","timestamp":1756980174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01506-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1506"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01506-0","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"10 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}